| Literature DB >> 21036042 |
Steven P Tanis1, Michael B Plewe, Ted W Johnson, Scott L Butler, Deepak Dalvie, Dorothy DeLisle, Klaus R Dress, Qiyue Hu, Buwen Huang, Jon E Kuehler, Atsuo Kuki, Wen Liu, Qinghai Peng, Graham L Smith, Jim Solowiej, Khanh T Tran, Hai Wang, Anle Yang, Chunfeng Yin, Xiaoming Yu, Junhu Zhang, Huichun Zhu.
Abstract
HIV-1 integrase is one of three enzymes encoded by the HIV genome and is essential for viral replication, and HIV-1 IN inhibitors have emerged as a new promising class of therapeutics. Recently, we reported the discovery of azaindole hydroxamic acids that were potent inhibitors of the HIV-1 IN enzyme. N-Methyl hydroxamic acids were stable against oxidative metabolism, however were cleared rapidly through phase 2 glucuronidation pathways. We were able to introduce polar groups at the β-position of the azaindole core thereby altering physical properties by lowering calculated log D values (c Log D) which resulted in attenuated clearance rates in human hepatocytes. Pharmacokinetic data in dog for representative compounds demonstrated moderate oral bioavailability and reasonable half-lives. These ends were accomplished without a large negative impact on enzymatic and antiviral activity, thus suggesting opportunities to alter clearance parameters in future series.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21036042 DOI: 10.1016/j.bmcl.2010.10.022
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823